OKYO Pharma Limited Ordinary Shares

OKYO Pharma Limited Ordinary Shares

Compare this stock

OKYO Stock Report Card

$

VolatilityTechnicalsProfitPerformance

19%

Performance

Score:

10/100

OKYO returned -15.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

Score:

21/100

OKYO receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Profit

Score:

10/100

Out of the last 20 quarters, OKYO has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

53/100

OKYO has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

OKYO Pharma Limited Ordinary Shares Summary

Nasdaq / OKYO
Healthcare
Biotechnology
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.